Lung-MAP – The Lung Cancer Master Protocol
Lung-MAP – A New Paradigm in Clinical Trials
What is Lung-MAP?
Lung-MAP is a cancer clinical trial designed to quickly and efficiently test new treatments for advanced non-small cell lung cancers – which make up about 85 percent of all lung cancer diagnoses in the United States. Lung-MAP is offered at hospitals and clinics all over the country, making it easier for patients with lung cancer to participate and get access to investigational treatments to fight their cancer. Learn more about the trial.
The Latest Lung-MAP Developments
As it starts its second decade, Lung-MAP has undergone another major update – referred to as Lung-MAP 3.0 – greatly broadening access to the trial by expanding the list of next-generation sequencing (NGS) tests that can be used in enrolling patients. We made this update because NGS testing has become a standard part of the treatment process for most patients with non-small cell lung cancer – the update keeps Lung-MAP as patient focused as possible.
Lung-MAP 3.0 simplifies screening, making clinical trials of new treatments available to even more patients at a wider range of community sites. Allowing the use of more NGS tests means Lung-MAP is even better positioned to enroll a group of patients fully representative of the diverse population of patients with advanced non-small cell lung cancer in the U.S.
About Lung-MAP
Lung-MAP is the first large-scale precision medicine trial in lung cancer supported by the National Cancer Institute (NCI), part of the federal National Institutes of Health, and is the first major NCI trial to test multiple treatments, simultaneously, under one “umbrella” design – which makes Lung-MAP more flexible and more efficient than typical cancer trials, and speeds the development process for new cancer drugs.
Lung-MAP is also an unprecedented public-private partnership, one that includes not only the NCI and the four adult cancer research groups in its National Clinical Trials Network, but also Friends of Cancer Research (Friends), the Foundation for the National Institutes of Health, Foundation Medicine, pharmaceutical companies, and several lung cancer advocacy organizations.
Lung-MAP Quotes
"This trial is breaking down the old paradigms of traditional clinical trials, allowing multiple enrollees to be tested and assigned to the treatment most likely to work for them"